 |
13 Companies | 15 Products |
|
|
15 Products | |
46 Diseases | |
8 Trials |  |
488 News |  |
| «12...567891011121314151617» |
- ||| Clinical: Now about those cases that turn around and relapse CD33+ or have FLT3-ITD... (Twitter) - Mar 23, 2020
- | Review, Journal: Microglia in Alzheimer's Disease: Exploring how Genetics and Phenotype Influence Risk. (Pubmed Central) - Mar 22, 2020
Microglia are quite sensitive to their local environment, suggesting the need to more fully recapitulate an in vivo environment to study this highly plastic cell type. Likely only by combining the above approaches, will the field fully elucidate the molecular pathways that regulate microglia and influence neurodegeneration, in turn uncovering potential new targets for future therapeutic development.
- || Clinical, Journal, Myeloid-derived suppressor cells: Myeloid-derived suppressor cells induce regulatory T cells in chronically HBV infected patients with high levels of hepatitis B surface antigen and persist after antiviral therapy. (Pubmed Central) - Mar 22, 2020
We established a previously unrecognised role of MDSC in Treg development in IT and EP-/EN-CHB via TGF-β/IL-10-dependent pathways and both cell-types persisted after anti-viral therapy. Hence, therapeutic targeting of MDSC or reducing circulating HBsAg level together with tenofovir-therapy might be more effective in restricting HBV persistence and disease progression.
- || Biomarker, Clinical, Journal, Myeloid-derived suppressor cells: Circulating myeloid-derived suppressor cells: An independent prognostic factor in patients with breast cancer. (Pubmed Central) - Mar 18, 2020
Moreover, increased circulating MDSC levels robustly associate with advanced BC stage and positive lymph node status. By being more abundant and more effective T cell suppressors, BC patient-derived circulating MDSCs exert a dual immunosuppressive effect. Our findings pave the way to develop novel diagnostic and immunotherapeutic strategies, aimed at detecting and inhibiting MDSCs in patients with BC.
- | Journal: The non-apoptotic role of caspase-9 promotes differentiation in leukemic cells. (Pubmed Central) - Mar 18, 2020
Notably, all of the events occur when cell viability remains constant. Owing to the evidence, caspase-9 activity is considered as a central factor in the execution of differentiation in leukemic cells.
- | Journal: Bringing Order out of Chaos: Establishing an Epistatic Relationship between CD33 and TREM2. (Pubmed Central) - Mar 18, 2020
In this issue of Neuron, Griciuc et al. (2019) demonstrate opposing effects of CD33 and TREM2 on AD phenotypes, where CD33 deletion promotes neuroprotection in a manner dependent on TREM2.
- | Journal: Leukemic cell kinetics of APL with a novel complex variant t (12;17;15)(p13;q21;q22) (Pubmed Central) - Mar 14, 2020
Quantitative evaluation of the differentiated leukemic cells of APL and recovered cells from normal hematopoiesis in PB can provide useful information for a safer induction therapy. No significant difference was noted in the kinetics of the leukemic cells under ATRA treatment as well as in the clinical features between our patient without RARA-PML and those with t (15;17), which is a cytogenetic evidence for the critical role of PML-RARA in the pathogenesis of APL.
- | Journal: Is Alzheimer disease a failure of mobilizing immune defense? Lessons from cognitively fit oldest-old. (Pubmed Central) - Mar 13, 2020
iii) Does central nervous system (CNS) repair in aging depend on recruitment of the elements of cellular adaptive immune response such as effector T cells, and can the recruitment of systemic immune cells ameliorate AD neuropathology? iv) How effective are the immune-system-based therapeutic approaches currently employed for the treatment of AD?
- || Clinical, Journal: Immunophenotypic Profile of CD34+ Subpopulations and Their Role in the Diagnosis and Prognosis of Patients with De-Novo, Particularly Low-Grade Myelodysplastic Syndromes. (Pubmed Central) - Mar 10, 2020
iv) How effective are the immune-system-based therapeutic approaches currently employed for the treatment of AD? A new scoring system based on the expression of immature cell antigens on CD34+ cells (by itself or in combination with the Ogata score) can discriminate lower risk MDS patients, including those with normal karyotype, from the normal control group.
- | azacitidine / Generic mfg., decitabine / Generic mfg.
Review, Journal, IO Biomarker: New drugs creating new challenges in acute myeloid leukemia. (Pubmed Central) - Mar 10, 2020
This flurry of new drug approvals has markedly altered the treatment landscape in AML and provided new opportunities, as well as new challenges for treating clinicians. This review will focus on how these drugs might shape clinical practice and the hurdles likely to be faced by new therapies seeking entry into this dynamic and rapidly changing therapeutic landscape.
- Venclexta (venetoclax) / Roche, AbbVie
Venetoclax and Hypomethylating Agents for the Treatment of Newly Diagnosed Acute Myeloid Leukemia () - Mar 9, 2020 - Abstract #HOPA2020HOPA_400;
Results to be presented at HOPA Annual Conference in March 2020. Conclusions/ Results to be presented at HOPA Annual Conference in March 2020.
- PHENOTYPICAL CHARACTERIZATION OF INDUCED CD33+ AND CD11b+ MYELOID CELLS FROM PERIPHERAL BLOOD AFTER CO-CULTURE WITH A METASTATIC UVEAL MELANOMA CELL LINE (Exhibit Hall: Posterboard# A0036) - Mar 9, 2020 - Abstract #ARVO2020ARVO_3435;
This indicates the ability of metastatic uveal melanoma to induce MDSCs. MDSCs are a major obstacle for immunotherapy, therefore the study of immunotolerance in UM is relevant considering a potential target in adjunctive therapy.
- | Review, Journal: Sialic acid-binding immunoglobulin-like lectins (Siglecs) detect self-associated molecular patterns to regulate immune responses. (Pubmed Central) - Mar 8, 2020
We also provide an overview of the known interactions of Siglec receptors and sialoglycan-SAMPs. Manipulation of the Siglec-SAMP axis offers new therapeutic opportunities for the treatment of inflammatory conditions, autoimmune diseases and also cancer immunotherapy.
- | Review, Journal: Hematological malignancies and molecular targeting therapy. (Pubmed Central) - Mar 8, 2020
The first memorable success in this field was imatinib, a first-generation tyrosine kinase inhibitor (TKI), which has been applied in chronic myeloid leukemia (CML) since 2001...Recently, the second generation TKIs, dasatinib, nilotinib, and ponatinib, have also been available for CML patients...Notably, chemotherapy plus midostaurin improved survival compared with chemotherapy alone...Gemtuzumab ozogamicin, a selective anti-CD33 antibody-calicheamicin conjugate, is approved for clinical practice. Many molecular targeting agents are now being used for hematological malignancies.
- SYSTEMATIC ASSESSMENT OF HTA DECISIONS FOR PERSONALIZED MEDICINES FOR AN ORPHAN DISEASE- ACUTE MYELOID LEUKEMIA (AML) () - Mar 8, 2020 - Abstract #ISPOR2020ISPOR_1717;
Major factors driving decisions were, superior efficacy and acceptable safety for HAS and G-BA; clinical benefit and cost-effectiveness for pCODR, PBAC, NICE and SMC; and end of life criteria across HTAs. Cost-effectiveness for NICE, SMC was by PAS under a commercial agreement with manufacturers.
- | nedisertib (M3814) / EMD Serono, Mylotarg (gemtuzumab ozogamicin) / UCB, PDL, Pfizer
Journal: DNA-PK Inhibitor, M3814, as a New Combination Partner of Mylotarg in the Treatment of Acute Myeloid Leukemia. (Pubmed Central) - Mar 3, 2020
Combination of M3814 with Mylotarg in two AML xenograft models, MV4-11 and HL-60, demonstrated increased efficacy and significantly improved survival benefit without elevated body weight loss. Our results support a new application for pharmacological DNA-PK inhibitors as enhancers of Mylotarg and a potential new combination treatment option for AML patients.
- MitoQ (mitoquinone) / Antipodean
[VIRTUAL] MitoQ ATTENUATES EX VIVO PROATHEROGENIC EFFECTS OF HIV PLASMA IN CHRONIC TREATED HIV ([VIRTUAL]) - Mar 2, 2020 - Abstract #CROI2020CROI_1290;
MitoQ attenuated proatherogenic effects of HIV-plasma from patients on potent ART with no clinical CVD in ex vivo model of arterial wall. The role of MitoQ in CVD in chronic treated HIV needs to be further studied in vivo.
- Monocytes from IgE- and IgE+ Adults with Allergies and Asthma Continue to Express Inducible Nitric Oxide Synthase (iNOS) after Frozen Storage. (Convention Center, 200 Level, Hall D) - Mar 1, 2020 - Abstract #AAAAI2020AAAAI_1103;
The role of MitoQ in CVD in chronic treated HIV needs to be further studied in vivo. Expression of intracellular iNOS by CD33+ monocytes is maintained and not significantly altered after frozen storage of PBMC from IgE- and IgE+ adults.
- Inflammatory and genetic signatures for recurrent oropharynx cancer (The Westin Kierland Resort and Spa) - Feb 27, 2020 - Abstract #MHNCS2020MHNCS_228;
Expression of intracellular iNOS by CD33+ monocytes is maintained and not significantly altered after frozen storage of PBMC from IgE- and IgE+ adults. While overall inflammation may be increased in HPV+ patients with recurrent disease, based on the current study, the tumor associated inflammation may be contributing to an enhanced immunosuppressive environment.
- Keytruda (pembrolizumab) / Merck (MSD), Erbitux (cetuximab) / Eli Lilly, EMD Serono
[VIRTUAL] Initial correlative studies from a trial of cetuximab and pembrolizumab in metastatic colorectal cancer (mCRC). (Poster Board 54) - Feb 27, 2020 - Abstract #ASCO2020ASCO_315;
P1/2
The treatment associated increase in intratumoral CTLs was particularly pronounced, consistent with their local expansion and/or influx. This was accompanied by a decrease in PB CTLs.
- | vistusertib (AZD2014) / AstraZeneca, Mylotarg (gemtuzumab ozogamicin) / UCB, PDL, Pfizer
Journal: An mTORC1/2 dual inhibitor, AZD2014, acts as a lysosomal function activator and enhances gemtuzumab ozogamicin-induced apoptosis in primary human leukemia cells. (Pubmed Central) - Feb 26, 2020
These results indicate that AZD2014 activated lysosomal function in primary leukemia cells, which in turn enhanced the cytotoxicity of GO. Enhancement of lysosomal activity may represent a new therapeutic strategy in the treatment of GO and other ADCs, particularly in cases with low lysosomal activity.
- || Clinical, Journal: Characterization of Immunophenotypic Aberrancies in Adult and Childhood Acute Lymphoblastic Leukemia: Lessons from Regional Variation. (Pubmed Central) - Feb 26, 2020
Significant differences were observed in antigen-expression patterns between adult and childhood ALLs. Further studies are needed to correlate specific markers with recurrent cytogenetic abnormalities and prognosis with therapeutic response.
- | Journal: CD33 recruitment inhibits IgE-mediated anaphylaxis and desensitizes mast cells to allergen. (Pubmed Central) - Feb 25, 2020
We showed that high levels of CD33 were consistently expressed on human skin mast cells, and that the antigenic-liposomes with CD33 ligand prevented IgE-mediated bronchoconstriction in slices of human lung. The results demonstrated the potential of exploiting CD33 to desensitize mast cells to provide a therapeutic window for administering allergen immunotherapy without triggering anaphylaxis.
- | Journal: Controversies about the subcellular localization and mechanisms of action of the Alzheimer's disease-protective CD33 splice variant. (Pubmed Central) - Feb 25, 2020
The results demonstrated the potential of exploiting CD33 to desensitize mast cells to provide a therapeutic window for administering allergen immunotherapy without triggering anaphylaxis. No abstract available
- || Clinical, Journal: Analysis of Clinical Characteristics of Acute B Lymphoblastic Leukemia with EP300-ZNF384 Fusion Gene Positive (Pubmed Central) - Feb 23, 2020
The B-ALL with EEP300-ZNF384 fusion gene positive may be a subgroup of B-ALL with a uniqe clinical characteristis and laboatorial features. EP300-ZNF384 positive patients show a good response to conventional chemotherapy, suggesting a favorable prognosis.
- || Clinical, Retrospective data, Journal: Relation of ASXL2 Gene Mutation with Clinical Characteristics, Prognosis and C-KIT Gene Mutation in AML Patients with AML1- ETO Fusion Gene (Pubmed Central) - Feb 23, 2020
Among AML patients with AML1-ETO fusion gene, ASXL2 gene mutation accounts for a certain ratio, and the peripheral blood hemoglobin concentration and CD33 expression in these patients are often low. At the same time, ASXL2 gene mutation may not be closely related with C-KIT gene mutation.
- || Clinical, Review, Journal, IO biomarker: Harnessing T Cells to Target Pediatric Acute Myeloid Leukemia: CARs, BiTEs, and Beyond. (Pubmed Central) - Feb 23, 2020
In this review we focus on AML-specific T cell engaging bispecific antibodies and chimeric antigen receptor (CAR) T cells. We review antigens being explored for T cell-based immunotherapy in AML, describe the landscape of clinical trials upcoming for bispecific antibodies and CAR T cells, and highlight strategies to overcome additional challenges facing translation of T cell-based immunotherapy for AML.
- || Mylotarg (gemtuzumab ozogamicin) / UCB, PDL, Pfizer
Biomarker, Clinical, Journal: ABCB1 SNP predicts outcome in patients with acute myeloid leukemia treated with Gemtuzumab ozogamicin: a report from Children's Oncology Group AAML0531 Trial. (Pubmed Central) - Feb 22, 2020
Our results show the significance of ABCB1 SNPs on GO response in AML and warrants the need to investigate this in other cohorts. Once validated, ABCB1-SNPs in conjunction with CD33-SNPs can open up opportunities to personalize GO-therapy.
- | Journal: Recruiting CD33 on mast cells to inhibit IgE-mediated mast cell-dependent anaphylaxis. (Pubmed Central) - Feb 20, 2020
However, this strategy only worked if both the antigen (reactive with the mast cell-bound IgE) and CD33L were on the same liposome. This approach promises to rapidly reduce IgE-dependent mast cell activation in response to challenge with offending allergens.
- | Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
Journal: CD33+ Immature Myeloid Cells Critically Predict Recurrence in Advanced Gastric Cancer. (Pubmed Central) - Feb 15, 2020
Recruitment of CD33+ immature myeloid cells critically predict hematogenous recurrences in curatively resected advanced GC. These results give rational to focusing on CD33+ myeloid-derived cells as a novel approach to tackle advanced GC.
- | Mylotarg (gemtuzumab ozogamicin) / UCB, PDL, Pfizer
Journal, Myeloid-derived suppressor cells, IO Biomarker: MDSC targeting with Gemtuzumab ozogamicin restores T cell immunity and immunotherapy against cancers. (Pubmed Central) - Feb 14, 2020
In the rare conditions of HLH/MAS gemtuzumab ozogamicin provides a novel anti-myeloid strategy. FUND: This work was supported by Cancer Research UK, CCLG, Treating Children with Cancer, and the alumni and donors to the University of Birmingham.
- Mozobil (plerixafor) / Sanofi
[VIRTUAL] CD34 + CELL SUBSETS IN STEM CELL PRODUCTS AND THEIR RELATIONSHIP WITH ENGRAFTMENT KINETICS (ePoster Area) - Feb 8, 2020 - Abstract #EBMT2020EBMT_2342;
In accordance with the literature data, the three different mobilization regimens did not provide adequate MLP and BLP in the peripheral blood. Early engraftment kinetics were not affected by given CD34+ cell subsets.
- [VIRTUAL] ANTI-CD3/CD33 BISPECIFIC ANTIBODIES EFFICIENTLY REDIRECT DONOR T CELLS AGAINST HLA LOSS LEUKEMIA RELAPSES (ePoster Area) - Feb 8, 2020 - Abstract #EBMT2020EBMT_2081;
Our results demonstrate that anti-CD3/CD33 BsAbs can effectively redirect donor T cells against HLA loss leukemia variants, resulting in their rapid and effective killing. Taken together, these promising findings strongly support translation of this approach to clinical trials, to provide a rational therapy for this increasingly recognized but still treatment-orphan modality of post-transplantation relapse.
- [VIRTUAL] AN UPDATE OF THE EBMT SURVEY ON CAR T-CELL ACTIVITY IN EUROPE. ON BEHALF OF THE CELLULAR THERAPY & IMMUNOBIOLOGY WORKING PARTY (CTIWP) (ePoster Area) - Feb 8, 2020 - Abstract #EBMT2020EBMT_2018;
Adult patients with NHL now represent the most frequent indication for treatment, because of commercial availability of approved products in this indication. The use of marketed CAR T-cells has increased by 10-fold within 6 months, but still represents a minority of the ongoing activity.
- [VIRTUAL] MYELOID-DERIVED SUPPRESSOR CELLS RECOVER QUICKLY FOLLOWING AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA PATIENTS (ePoster Area) - Feb 8, 2020 - Abstract #EBMT2020EBMT_1626;
Relative counts of circulating PMN-MDSCs and M-MDSCs in MM patients were significantly higher compared with healthy donor values. MDSC populations restored rapidly following AHSCT, and reached pre-transplant levels at the day of engraftment.
- [VIRTUAL] IMPACT OF PRE-TRANSPLANT MRD BURDEN MEASURED BY MULTICOLOR FLOW CYTOMETRY ON RELAPSE AND SURVIVAL IN AML PATIENTS UNDERGOING ALLO-SCT IN CR (ePoster Area) - Feb 8, 2020 - Abstract #EBMT2020EBMT_1589;
The former group of patients may need further pre- or/and post-transplant strategies to reduce relapses. Clinical Trial Registry: not applicable
- cyclophosphamide intravenous / Generic mfg.
[VIRTUAL] EVOLUTION OF DONOR CHIMERISM AFTER HAPLOIDENTICAL STEM CELL TRANSPLANT - CLINICAL CORRELATIONS (ePoster Area) - Feb 8, 2020 - Abstract #EBMT2020EBMT_1074;
Notwithstanding, most of the RIC patients also achieved full donor chimerism. There wasn't a correlation between loss of CD3+ chimerism and disease relapse.
- [VIRTUAL] A PILOT FEASIBILITY STUDY OF NON-MYELOABLATIVE ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR REFRACTORY CROHN DISEASE (ePoster Area) - Feb 8, 2020 - Abstract #EBMT2020EBMT_927;
Alternatively, the infused donor graft may have provided a non-CD3+, non-CD33+ non-hematopoietic type of stem cell such as donor mesenchymal stem cells that in theory could facilitate a durable remission. Clinical Trial Registry: FDA IND 16908, www.clinicaltrials.gov NCT 01288053
- Mylotarg (gemtuzumab ozogamicin) / UCB, PDL, Pfizer
[VIRTUAL] GEMTUZUMAB-OZOGAMICIN FOR BRIDGING TO TRANSPLANT IN REFRACTORY/RELAPSED CD33 POSITIVE ACUTE LEUKEMIA - IS IT WORTHWHILE? (ePoster Area) - Feb 8, 2020 - Abstract #EBMT2020EBMT_868;
In our single center retrospective analysis of CD33 positive AL patients, bridging to transplant with GO seemed to have limited impact on long-term OS and DFS. However, even in refractory/relapsed AL, alloHSCT was able to rescue about one third of patients.
- Mylotarg (gemtuzumab ozogamicin) / UCB, PDL, Pfizer
[VIRTUAL] GO-FLAG REGIMEN AS A BRIDGE THERAPY TO ALLOGENEIC STEM CELL TRANSPLANTATION IN REFRACTORY/RELAPSED AML PATIENTS (ePoster Area) - Feb 8, 2020 - Abstract #EBMT2020EBMT_854;
Gemtuzumab ozogamicin (GO) is a recombinant, humanized anti-CD33 monoclonal antibody covalently attached to the cytotoxic antitumor antibiotic calicheamicin, which effectiveness depends on more than 75% expression of CD33-glycoprotein on leukemic blasts... GO-FLAG demonstrated the efficacy and acceptable toxicity in pts with r/rAML and can be used as a bridge to alloHSCT.
- | azacitidine / Generic mfg.
Journal, PD(L)-1 Biomarker, IO Biomarker: Targeting the arginine metabolic brake enhances immunotherapy for leukaemia. (Pubmed Central) - Feb 7, 2020
Inhibition of arginine metabolism enhanced the proliferation and cytotoxicity of anti-NYESO T cells against AZA/VOR treated AML blasts, and can boost anti-CD33 Chimeric Antigen Receptor-T cell cytotoxicity. Therefore measurement of plasma arginine concentrations in combination with therapeutic targeting of arginase activity in AML blasts could be a key adjunct to immunotherapy.
- || Review, Journal: CD33 in Alzheimer's Disease - Biology, Pathogenesis, and Therapeutics: A Mini-Review. (Pubmed Central) - Feb 7, 2020
This review summarizes the recently advanced biology of CD33 and its association with AD. It also provides insights from a drug discovery perspective into the druggability, therapeutic strategies, and challenges to target CD33 for treating this devastating disorder.
- | Journal, IO biomarker: Biology and prognostic impact of clonal plasmacytoid dendritic cells in chronic myelomonocytic leukemia. (Pubmed Central) - Feb 7, 2020
Finally, an excess of pDCs correlates with regulatory T cell accumulation and an increased risk of acute leukemia transformation. These results demonstrate the FLT3L-independent accumulation of clonal pDCs in the bone marrow of CMML patients with mutations affecting the RAS pathway, which is associated with a higher risk of disease progression.
- Immune Cell Profiles Predicting Thyroid Cancer Prognosis (Room 3) - Feb 7, 2020 - Abstract #ENDO2020ENDO_2767;
We have demonstrated that aggressive thyroid cancer at presentation or during follow-up is characterized by a circulating immunophenotype comprising of increased immune suppressor cells (regulatory T cells, MDSCs, effector memory T cells) but decreased immune activator cells (CD4+ T cells, gamma delta T cells, NK T-like cells, central memory T cells) as compared to less aggressive thyroid cancer. This circulating immunophenotype serves as a biomarker for cancer prognosis and could guide use of novel immunotherapies for advanced thyroid cancer.
- || molibresib (GSK525762) / GSK
Clinical, Journal, PD(L)-1 Biomarker, IO Biomarker: Targeting monocyte-intrinsic enhancer reprogramming improves immunotherapy efficacy in hepatocellular carcinoma. (Pubmed Central) - Jan 30, 2020
This circulating immunophenotype serves as a biomarker for cancer prognosis and could guide use of novel immunotherapies for advanced thyroid cancer. Our results signify how non-tumour-intrinsic properties in the desmoplastic microenvironment can be exploited to reinstate immunosurveillance, providing readily translatable combination strategies to empower HCC immunotherapy.
- | Journal: SRSF1 and PTBP1 are trans-acting factors that suppress the formation of a CD33 splicing isoform linked to Alzheimer's disease risk. (Pubmed Central) - Jan 28, 2020
Our findings shed light on molecular interactions that regulate CD33 exon-2 splicing, ultimately impacting receptor expression on the cell surface. These data aid in the understanding of CD33's regulation of microglial signaling underpinning the AD genetic associations.
- | Review, Journal: Cellular therapy for acute myeloid Leukemia - Current status and future prospects. (Pubmed Central) - Jan 27, 2020
It is unknown whether such approaches targeting AML will spare normal hematopoiesis or would need to be used in combination with hematopoietic stem cell transplantation. Here we review the current state of cell therapy for patients with AML and consider future prospects.
- | daunorubicin / Generic mfg., Hikma
Journal: CD123/CD33 dual-antibody modified liposomes effectively target acute myeloid leukemia cells and reduce antigen-negative escape. (Pubmed Central) - Jan 24, 2020
Here we described the development and specific targeting of daunorubicin (DNR)-loaded CD123/CD33 dual-antibody modified liposome, CD123/CD33-LP-DNR...The results indicated that CD123/CD33-LP-DNR might present an effective delivery strategy to enhance the targeting ability against AML cells and potentially reduce the antigen-negative escape. Chemotherapeutics.
- Clinical, Immunophenotypic and Genomic Findings of NK-lymphoblastic Leukemia (LACC 403 A) - Jan 24, 2020 - Abstract #USCAP2020USCAP_2253;
We also found IKZF1 deletions and ETV6 mutations in NK-LL, which has not been previously reported. RUNX1, NOTCH1 and WT1 mutations, which are seen in our cases of T-LL and AUL, were not seen in our NK-LL cases.
- Prognostic Significance and Genomic Correlates of Myeloid Cell Populations in the Pancreatic Cancer Microenvironment (LACC West Exhibit Hall A, Poster Board Number: 163) - Jan 24, 2020 - Abstract #USCAP2020USCAP_2175;
Myeloid cell densities are associated with the status of driver genes TP53 and SMAD4. Our results highlight the value of using multimarker approaches to interrogate myeloid cell phenotypes and significance in the PDAC microenvironment.